Medigene AG (MDG1.DE)
| Previous close | 1.4400 |
| Open | 1.4200 |
| Bid | 1.4350 x 57900 |
| Ask | 1.4600 x 150900 |
| Day's range | 1.4000 - 1.4600 |
| 52-week range | 1.3100 - 2.9000 |
| Volume | |
| Avg. volume | 35,132 |
| Market cap | 37.118M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6300 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.60 |
GlobeNewswireMedigene to Present at Upcoming Conferences
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024. 21st CIMT Annual Meeting htt
- GlobeNewswire
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis antigen, which is expressed in multip
- GlobeNewswire
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit held in Amsterdam, Netherland
